SCHEMBL7144151

SCHEMBL7144151

COc1ccc(C(=O)N2C[C@@H](S)C[C@H]2C(=O)N(C)Cc2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.49
LMNA P02545 1/20 0.49
MAPK1 P28482 1/20 0.48
ACHE P22303 1/20 0.46
CPT2 P23786 1/20 0.46
CPT1A P50416 1/20 0.46
TSHR P16473 1/20 0.46
RECQL P46063 1/20 0.46
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
ALDH1A1 P00352 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
ALOX12 P18054 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GPR55 Q9Y2T6 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MMP1 P03956 1/20 0.42
MMP3 P08254 1/20 0.42
MMP13 P45452 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7137929 0.86 ACHE (0.46) ACHECPT2CPT1A
SCHEMBL7135172 0.86 MEN1 (0.46) SMN1; SMN2LMNACPT2CPT1AMEN1
SCHEMBL7150475 0.86 MEN1 (0.46) SMN1; SMN2LMNACPT2CPT1AMEN1
SCHEMBL7137783 0.81 CPT2 (0.48) SMN1; SMN2CPT2CPT1AKMT2AHTT
SCHEMBL7143331 0.80 MMP1 (0.58) SMN1; SMN2LMNAMAPK1ALDH1A1MMP1
SCHEMBL7140190 0.79 CPT2 (0.49) SMN1; SMN2CPT2CPT1AALDH1A1HTT
SCHEMBL7143079 0.79 CPT2 (0.47) SMN1; SMN2LMNACPT2CPT1A
SCHEMBL7139208 0.78 CPT2 (0.46) SMN1; SMN2LMNACPT2CPT1AHTT
SCHEMBL7144165 0.77 CPT2 (0.44) SMN1; SMN2CPT2CPT1AALDH1A1HTT
SCHEMBL7144688 0.75 ECE1 (0.46) SMN1; SMN2LMNAMAPK1CPT2CPT1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP SMN1; SMN2 3409/4885LMNA 4821/4885MAPK1 4292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.